Luiz Henrique Junqueira Dieckmann

Dr. Luiz Henrique Junqueira Dieckmann

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2014 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
LDLuiz Henrique Junqueira Dieckmann
Luiz Henrique Junqueira Dieckmann
ARAnna Carolina Ramos
Anna Carolina Ramos
ESEroy Aparecida Silva
Eroy Aparecida Silva
LJLuis Pereira Justo
Luis Pereira Justo
PSPamela Sabioni
Pamela Sabioni
JGJosé Carlos F Galduróz
José Carlos F Galduróz

5 November 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
JMJair Mari
Jair Mari
LDLuiz Henrique Junqueira Dieckmann
Luiz Henrique Junqueira Dieckmann
DPDaniel Prates-Baldez
Daniel Prates-Baldez
MHMichel Haddad
Michel Haddad
Naielly Rodrigues da SilvaNaielly Rodrigues da Silva
Naielly Rodrigues da Silva
FKFlavio Kapczinski
Flavio Kapczinski
Objective This study aims to conduct an overview on the comparative efficacy of valproate in acute mania, bipolar depression and maintenance treatment of bipolar disorder (BD). Method We performed an overview of systematic reviews with meta-analyses of randomised controlled trials (RCTs), registered in PROSPERO (CRD42024497749). We searched Medline and Cochrane Database of Systematic Reviews. Summary measures comparing valproate with placebo or other active drugs were described. Results We included 26 systematic reviews. For acute mania (31 RCTs, n=4376), valproate showed a significantly better response than placebo in two high-quality systematic reviews (RR=1.42; 95% CI: 1.19 to 1.71) (OR=2.05; 95% CI: 1.32 to 3.20). No significant differences with lithium were found in most outcomes. Valproate had similar efficacy to quetiapine and lower efficacy compared with risperidone, with conflicting results when compared with olanzapine. In bipolar depression (7 RCTs, n=399), valproate was more effective than placebo in reducing depressive symptoms (OR=2.80; 95% CI: 1.26 to 6.18) and achieving remission (OR=2.4; 95% CI: 1.09 to 5.29) (OR=2.15; 95% CI: 0.82 to 5.6), considering the results of three high-quality systematic reviews. No significant difference was observed with lithium, lurasidone, quetiapine or olanzapine plus fluoxetine, but valproate showed superior efficacy to aripiprazole, ziprasidone and agomelatine. In maintenance treatment (11 RCTs, n=1063), valproate was superior to placebo in preventing relapse of any mood episode in two high-quality systematic reviews (RR=0.63; 95% CI: 0.48 to 0.83) (RR=0.63; 95% CI: 0.47 to 0.83). No significant difference was found with lithium, olanzapine or lamotrigine. Conclusion This overview highlights favourable results for valproate compared with placebo in all phases of BD, as well as presenting specific results in comparison with other active drugs. However, these results must be interpreted considering the methodological limitations of our study.

1 December 2009 in Revista Brasileira de Educação Médica
Verified
Journal Article
Open access
PDF file
PDPaula Natalie Arraes Guedes Macedo Dieckmann
Paula Natalie Arraes Guedes Macedo Dieckmann
LNLuciana Loureiro Nardotto
Luciana Loureiro Nardotto
LDLuiz Henrique Junqueira Dieckmann
Luiz Henrique Junqueira Dieckmann
YFYngrid Dieguez Ferreira
Yngrid Dieguez Ferreira
BMBarbara Arraes Guedes Macedo
Barbara Arraes Guedes Macedo
MMMario Alfredo De Marco
Mario Alfredo De Marco
OBJECTIVES: 1 - Verify the prevalence of depressive symptoms in first to fourth-year medical students using the Beck Depression Inventory (BDI). 2 - Establish correlations between target factors and higher or lower BDI scores. 3 - Investigate the relationship between the prevalence of depressive symptoms and the demand for psychological care offered by the Centro Universitário Lusíada. METHOD: Cross-sectional study of 290 first to fourth-year medical students; implementation of the BDI, socio-demographic survey, and evaluation of satisfaction with progress. RESULTS: The study sample was 59% female and 41% male. Mean BDI was 6.3 (SD 5.8). Overall prevalence of depressive symptoms was 23.1%. The following associations were statistically significant (p<0.05): among students for whom the course failed to meet original expectations, who were dissatisfied with the course, or who came from the interior of the State (20.5%, 12.5%, and 24.4% of the total sample, respectively), for 40%, 36.1% and 36.4%, respectively, the BDI was consistent with some degree of depression. CONCLUSION: The study showed that there is higher prevalence of depressive symptoms in medical students than in the general population

1 January 2023 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
PDF file
LFLuiz Gustavo Rachid Fernandes
Luiz Gustavo Rachid Fernandes
CWCarolyn Maria de Geus Wenceslau
Carolyn Maria de Geus Wenceslau
ASAndré Amaro Mamédio dos Santos
André Amaro Mamédio dos Santos
DLDiogo Von Gaevernitz Lima
Diogo Von Gaevernitz Lima
LDLuiz Henrique Junqueira Dieckmann
Luiz Henrique Junqueira Dieckmann
MSMarcelo Derbli Schafranski
Marcelo Derbli Schafranski
The aim of this study was to evaluate the factors that are most correlated with the levels of functional disability in patients with fibromyalgia.

1 September 2008 in Brazilian Journal of Psychiatry
Verified
Journal Article
Open access
PDF file
LNLuciana Vargas Nunes
Luciana Vargas Nunes
LDLuiz Henrique Junqueira Dieckmann
Luiz Henrique Junqueira Dieckmann
FLFernando Sargo Lacaz
Fernando Sargo Lacaz
RBRodrigo Affonseca Bressan
Rodrigo Affonseca Bressan
JMJair de Jesus Mari
Jair de Jesus Mari
Universidade Federal de São Paulo (UNIFESP) Departamento de Psiquiatria Programa de EsquizofreniaUniversidade Federal de São Paulo (UNIFESP) Departamento de PsiquiatriaUNIFESP, Depto. de Psiquiatria Programa de EsquizofreniaUNIFESP, Depto. de PsiquiatriaSciEL

29 May 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MHMichel Haddad
Michel Haddad
LDLuiz Henrique Junqueira Dieckmann
Luiz Henrique Junqueira Dieckmann
Naielly Rodrigues da SilvaNaielly Rodrigues da Silva
Naielly Rodrigues da Silva
PDPaula Natalie Arraes Guedes Macedo Dieckmann
Paula Natalie Arraes Guedes Macedo Dieckmann
TVThiago Viola
Thiago Viola
JMJair Mari
Jair Mari
Background/Objectives: Migraine is markedly more prevalent among individuals with bipolar disorder (BD) than in the general population. The two disorders share overlapping pathophysiological mechanisms, including neuroinflammation, oxidative stress, and genetic vulnerability. However, the potential bidirectional efficacy of pharmacological agents approved for one condition on the other remains unclear. This study aimed to evaluate cross-disorder pharmacological efficacy between migraine and bipolar disorder. Methods: We systematically searched Medline and the Cochrane Central Register of Controlled Trials (PROSPERO registration: CRD420251130780) for randomized controlled trials (RCTs) assessing (1) concurrent treatment effects in comorbid BD–migraine samples, (2) efficacy of migraine treatments in BD, or (3) efficacy of BD treatments in migraine. Searches included guideline-recommended drugs for either disorder, without language or date restrictions. Results: A total of 32 RCTs met the inclusion criteria. Fifteen studies evaluated migraine drugs in BD, and sixteen evaluated BD drugs in migraine. No RCTs were identified that simultaneously assessed both conditions within the same sample. Valproate was the only agent demonstrating consistent, replicated efficacy in both conditions, supporting true cross-disorder benefit. Haloperidol and chlorpromazine showed limited evidence for acute anti-migraine efficacy, based solely on placebo-controlled studies, whereas all other guideline-recommended BD drugs lacked evidence of benefit for migraine. Conversely, topiramate, while effective for migraine, was inferior to valproate in BD outcomes, and lamotrigine was effective for BD only when compared with placebo. Conclusions: Valproate remains the sole pharmacological agent with robust evidence of bidirectional efficacy in migraine and BD. Most other guideline-recommended medications show disorder-specific effects, highlighting the need for integrative trials addressing pharmacological overlap in comorbid migraine–BD samples.